Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.32 |
| ▸ | KRAS | P01116 | 2/20 | 0.31 |
| ▸ | RAF1 | P04049 | 2/20 | 0.31 |
| ▸ | BRAF | P15056 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 2/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | ARAF | P10398 | 1/20 | 0.31 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.31 |
| ▸ | CSK | P41240 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27103133 | 0.84 | FGFR1 (0.38) | LRRK2EGFRFGFR1SRCPDGFRB | |
| SCHEMBL27103106 | 0.84 | PRKCH (0.35) | EGFRFGFR1KRASRAF1BRAF | |
| SCHEMBL29699267 | 0.83 | RAF1 (0.38) | LRRK2EGFRFGFR1KRASRAF1 | |
| SCHEMBL15263527 | 0.83 | RAF1 (0.38) | LRRK2EGFRFGFR1KRASRAF1 | |
| SCHEMBL27103103 | 0.82 | FLT3 (0.39) | EGFRFGFR1KRASRAF1BRAF | |
| SCHEMBL24457928 | 0.81 | FGFR1 (0.47) | EGFRFGFR1SRCPDGFRBPDGFRA | |
| SCHEMBL24457853 | 0.81 | FGFR1 (0.40) | EGFRFGFR1SRCSIK1SIK2 | |
| SCHEMBL24457858 | 0.81 | LRRK2 (0.35) | LRRK2EGFRFGFR1KRASRAF1 | |
| SCHEMBL22625609 | 0.81 | KRAS (0.31) | KRASRAF1BRAFKDRSRC | |
| SCHEMBL22612825 | 0.81 | ULK1 (0.34) | KRASRAF1BRAFKDRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | LRRK2 177/4885EGFR 1301/4885FGFR1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.